Literature DB >> 20723571

Structural and functional insights into nuclear receptor signaling.

Lihua Jin1, Yong Li.   

Abstract

Nuclear receptors are important transcriptional factors that share high sequence identity and conserved domains, including a DNA-binding domain (DBD) and a ligand-binding domain (LBD). The LBD plays a crucial role in ligand-mediated nuclear receptor activity. Hundreds of different crystal structures of nuclear receptors have revealed a general mechanism for the molecular basis of ligand binding and ligand-mediated regulation of nuclear receptors. Despite the conserved fold of nuclear receptor LBDs, the ligand-binding pocket is the least conserved region among different nuclear receptor LBDs. Structural comparison and analysis show that several features of the pocket, like the size and also the shape, have contributed to the ligand binding affinity and specificity. In addition, the plastic nature of the ligand-binding pockets in many nuclear receptors provides greater flexibility to further accommodate specific ligands with a variety of conformations. Nuclear receptor coactivators usually contain multiple LXXLL motifs that are used to interact with nuclear receptors. The nuclear receptors respond differently to distinct ligands and readily exchange their ligands in different environments. The conformational flexibility of the AF-2 helix allows the nuclear receptor to sense the presence of the bound ligands, either an agonist or an antagonist, and to recruit the coactivators or corepressors that ultimately determine the transcriptional activation or repression of nuclear receptors.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20723571      PMCID: PMC2991384          DOI: 10.1016/j.addr.2010.08.007

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  89 in total

Review 1.  Ligand control of coregulator recruitment to nuclear receptors.

Authors:  Kendall W Nettles; Geoffrey L Greene
Journal:  Annu Rev Physiol       Date:  2005       Impact factor: 19.318

2.  Crystal structure of a mutant mineralocorticoid receptor responsible for hypertension.

Authors:  Jérôme Fagart; Jessica Huyet; Grégory M Pinon; Marina Rochel; Claudine Mayer; Marie-Edith Rafestin-Oblin
Journal:  Nat Struct Mol Biol       Date:  2005-05-22       Impact factor: 15.369

3.  The nuclear xenobiotic receptor CAR: structural determinants of constitutive activation and heterodimerization.

Authors:  Kelly Suino; Li Peng; Ross Reynolds; Yong Li; Ji-Young Cha; Joyce J Repa; Steven A Kliewer; H Eric Xu
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

4.  Structure of the murine constitutive androstane receptor complexed to androstenol: a molecular basis for inverse agonism.

Authors:  Li Shan; Jeremy Vincent; Joseph S Brunzelle; Isabelle Dussault; Min Lin; Irina Ianculescu; Mark A Sherman; Barry M Forman; Elias J Fernandez
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

5.  A structural basis for constitutive activity in the human CAR/RXRalpha heterodimer.

Authors:  Robert X Xu; Millard H Lambert; Bruce B Wisely; Erin N Warren; Emily E Weinert; Gregory M Waitt; Jon D Williams; Jon L Collins; Linda B Moore; Timothy M Willson; John T Moore
Journal:  Mol Cell       Date:  2004-12-22       Impact factor: 17.970

6.  Crystallographic identification and functional characterization of phospholipids as ligands for the orphan nuclear receptor steroidogenic factor-1.

Authors:  Yong Li; Mihwa Choi; Greg Cavey; Jennifer Daugherty; Kelly Suino; Amanda Kovach; Nathan C Bingham; Steven A Kliewer; H Eric Xu
Journal:  Mol Cell       Date:  2005-02-18       Impact factor: 17.970

7.  Structural and biochemical basis for selective repression of the orphan nuclear receptor liver receptor homolog 1 by small heterodimer partner.

Authors:  Yong Li; Mihwa Choi; Kelly Suino; Amanda Kovach; Jennifer Daugherty; Steven A Kliewer; H Eric Xu
Journal:  Proc Natl Acad Sci U S A       Date:  2005-06-23       Impact factor: 11.205

8.  Structural basis for an unexpected mode of SERM-mediated ER antagonism.

Authors:  Ya-Ling Wu; Xiaojing Yang; Zhong Ren; Donald P McDonnell; John D Norris; Timothy M Willson; Geoffrey L Greene
Journal:  Mol Cell       Date:  2005-05-13       Impact factor: 17.970

9.  Structural analyses reveal phosphatidyl inositols as ligands for the NR5 orphan receptors SF-1 and LRH-1.

Authors:  Irina N Krylova; Elena P Sablin; Jamie Moore; Robert X Xu; Gregory M Waitt; J Andrew MacKay; Dalia Juzumiene; Jane M Bynum; Kevin Madauss; Valerie Montana; Lioudmila Lebedeva; Miyuki Suzawa; Jon D Williams; Shawn P Williams; Rodney K Guy; Joseph W Thornton; Robert J Fletterick; Timothy M Willson; Holly A Ingraham
Journal:  Cell       Date:  2005-02-11       Impact factor: 41.582

10.  Structural disorder in the complex of human pregnane X receptor and the macrolide antibiotic rifampicin.

Authors:  Jill E Chrencik; Jillian Orans; Linda B Moore; Yu Xue; Li Peng; Jon L Collins; G Bruce Wisely; Millard H Lambert; Steven A Kliewer; Matthew R Redinbo
Journal:  Mol Endocrinol       Date:  2005-02-10
View more
  26 in total

1.  Structural basis for a molecular allosteric control mechanism of cofactor binding to nuclear receptors.

Authors:  Judit Osz; Yann Brélivet; Carole Peluso-Iltis; Vincent Cura; Sylvia Eiler; Marc Ruff; William Bourguet; Natacha Rochel; Dino Moras
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-21       Impact factor: 11.205

2.  Revealing a steroid receptor ligand as a unique PPARγ agonist.

Authors:  Shengchen Lin; Ying Han; Yuzhe Shi; Hui Rong; Songyang Zheng; Shikan Jin; Shu-Yong Lin; Sheng-Cai Lin; Yong Li
Journal:  Cell Res       Date:  2011-10-11       Impact factor: 25.617

3.  Delineation of the molecular determinants of the unique allosteric binding site of the orphan nuclear receptor RORγt.

Authors:  Iris A Leijten-van de Gevel; Luc Brunsveld
Journal:  J Biol Chem       Date:  2020-05-20       Impact factor: 5.157

Review 4.  Classical nuclear hormone receptor activity as a mediator of complex concentration response relationships for endocrine active compounds.

Authors:  Clifford J Cookman; Scott M Belcher
Journal:  Curr Opin Pharmacol       Date:  2014-10-06       Impact factor: 5.547

5.  Structural Dynamics of Agonist and Antagonist Binding to the Androgen Receptor.

Authors:  Ettayapuram Ramaprasad Azhagiya Singam; Phum Tachachartvanich; Michele A La Merrill; Martyn T Smith; Kathleen A Durkin
Journal:  J Phys Chem B       Date:  2019-09-03       Impact factor: 2.991

6.  Differential consequences of two distinct AhR ligands on innate and adaptive immune responses to influenza A virus.

Authors:  Jennifer L H Wheeler; Kyle C Martin; Emily Resseguie; B Paige Lawrence
Journal:  Toxicol Sci       Date:  2013-11-05       Impact factor: 4.849

7.  Solution Behavior of the Intrinsically Disordered N-Terminal Domain of Retinoid X Receptor α in the Context of the Full-Length Protein.

Authors:  Anna Belorusova; Judit Osz; Maxim V Petoukhov; Carole Peluso-Iltis; Bruno Kieffer; Dmitri I Svergun; Natacha Rochel
Journal:  Biochemistry       Date:  2016-03-15       Impact factor: 3.162

Review 8.  IGF binding proteins in cancer: mechanistic and clinical insights.

Authors:  Robert C Baxter
Journal:  Nat Rev Cancer       Date:  2014-04-10       Impact factor: 60.716

9.  Identification of the antibiotic ionomycin as an unexpected peroxisome proliferator-activated receptor γ (PPARγ) ligand with a unique binding mode and effective glucose-lowering activity in a mouse model of diabetes.

Authors:  W Zheng; X Feng; L Qiu; Z Pan; R Wang; S Lin; D Hou; L Jin; Y Li
Journal:  Diabetologia       Date:  2012-11-23       Impact factor: 10.122

10.  High Affinity Heme Binding to a Heme Regulatory Motif on the Nuclear Receptor Rev-erbβ Leads to Its Degradation and Indirectly Regulates Its Interaction with Nuclear Receptor Corepressor.

Authors:  Eric L Carter; Nirupama Gupta; Stephen W Ragsdale
Journal:  J Biol Chem       Date:  2015-12-15       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.